Results and Reports

Axis 1. Predictive Medicine (COHORTE Program)

The IMPaCT Cohort Axis has developed and launched the structure for recruiting the 200,000 participants who will take part in the prospective study. This structure consists of 50 nodes distributed throughout the entire country, including the 17 Autonomous Communities and the two Autonomous Cities.

A model of Informed Consent has been established for the collection and analysis of data and information gathered from participants.

In addition, the variables of interest for measurement have been selected and studied, along with the corresponding questionnaires, the biological samples to be collected, and the physical tests to be performed on participants. These components have been tested and validated in pre-pilot studies.

In 2023, recruitment of the first participants began in the Autonomous Communities of Aragón, Balearic Islands, Castilla-La Mancha, and Madrid.

Axis 2. Data Science (DATA Program)

The IMPaCT-Data Axis has developed a series of recommendations and best practices for collecting electronic health record information, medical images, and genomic data, as well as for ensuring interoperability among all this information.

Complementing this work, a cloud infrastructure architecture has been designed to provide a virtual research environment for the analysis of genomic, clinical, and medical imaging data. More information on the conceptualization of this cloud and demonstrators of the recommended technologies can be found at this link.

The axis has also compiled a set of software tools for data analysis, which are available at the bio.tools domain.

Axis 3. Genomic Medicine (GENÓMICA Program)

The IMPaCT Genomics Axis has developed a series of Standard Operating Procedures for the proper execution of genomic analyses and the management of the data obtained, as well as for the standardization and harmonization of the information and criteria used.

Expert groups have been formed within the axis in various disciplines. As a result of their work, a series of gene-specific and drug-specific guidelines have been produced, along with several models (diagnostic report, genetic report, clinical recommendation, etc.).

Policies have also been developed to ensure the protection of participants’ rights, which have been reviewed by the relevant ethics committees. The objectives are to guarantee transparency, respect for individuals’ decisions, traceability and security throughout the entire data handling process, and the protection of vulnerable individuals.

Reports
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.